Select your language/region

Q-linea’s ASTar – a success on ECCMID

Q-linea’s ASTar – a success on ECCMID

Q-linea AB (publ) (OMX: QLINEA), a diagnostic company focused on developing and delivering solutions to accurately and rapidly diagnose infectious diseases, now presents the final design of ASTar for potential customers at the most important trade fair; the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), this year being held in Amsterdam, 13-16 April.

At ECCMID, Q-linea primarily presents four news for ASTar:            

  • An even simpler workflow through a new graphical interface and a hands-on time less than one minute
  • Pre-production systems of ASTar
  • A common antibiotic panel for the US & EU markets with a large concentration range
  • The ability to also use ASTar as a semi-automatic system for, among other things, analysis of isolates

“We get great feedback. Especially on the antibiotic panel and how easy it is to handle. But also on the possibility of using ASTar as a semi-automatic system for, for example, isolates. Of course, it can be combined with our fully automatic workflow, which is much appreciated. Our broad antibiotic panel and the opportunity to analyze many different sample types is a great advantage and we feel that all work that has been done during the development is now given positive feedback from future customers,” said Jonas Jarvius, CEO of Q-linea.

At the fair, Q-linea shows the final design of ASTar in the pre-production systems which customers during the fair have the opportunity to see and feel. Being able to present ASTar systems that look as they will look at next year’s delivery is in line with Q-linea’s timetable and important as customers already need planning of their budgets to be able to buy the systems next year. Q-linea has received many notifications of interest that will be followed up in the coming weeks.

“Our very first ASTar customers will be our ambassadors for ASTar and we will work closely with them during the initial launch phase. Furthermore, we believe that we will be able to offer the system at a competitive price both for fully automatic and semi-automatic analysis of samples. During the fair, we have also had very good meetings with potential future sales partners,” said Jarvius.

During the fair, Q-linea also has two scientific presentations which, among other things, show Q-linea’s future ability to analyze urine and isolates, in addition to positive blood cultures. 

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB, 
+46 (0)70-323 77 60  

Anders Lundin, CFO, Q-linea AB  
+46 (0)70-600 15 20 

The information was submitted for publication, through the agency of the contact persons set out above, at 16:30 CET on 15 April 2019.

About Q-linea  

Q-linea is an innovative research, development and manufacturing company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea’s vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar™ is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit